YGYujing Gao

Yujing Gao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yujing Gao has a total of 119 co-authors. Here are the top co-authors by number of shared publications:

  • Xixi Chen

    Department of Pediatrics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    5 shared publications
  • Pu Li

    Department of Pediatrics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    4 shared publications
  • Xuehua Chen

    Department of Pediatrics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    4 shared publications
  • Yuanqi Gao

    Department of Pediatrics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    4 shared publications
  • Chun Pan

    Department of Pediatrics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    3 shared publications
  • Chundi Xu

    Department of Pediatrics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    3 shared publications

Latest Publications

  • Open Access

    Aspirin suppresses cytoprotective autophagy and colorectal tumorigenesis through HSP90AA1 K410 acetylation-mediated ULK1 ubiquitination and degradation

    by Fang Wang, Yuhuan Zhang, Xingchen Dai, Wei Gong, Mingdi Wang, Xiaoting Wu, Mingxiu Luo, Qinmei Ma, Hui Yan, Yujing Gao

    Colorectal cancer (CRC) remains a significant global health challenge with high recurrence rates despite therapeutic advancements, underscoring the urgency for innovative therapeutic strategies. Clinical trials have demonstrated that aspirin treatment correlates with reduced cancer incidence, recurrence, metastasis, and mortality, yet the precise intricacies of aspirin’s role in tumorigenesis and its underlying mechanisms remain incompletely understood. This study unveils the inhibitory impact of aspirin on CRC by suppressing cell cytoprotective autophagy. Mechanistically, aspirin increases the acetylation level of HSP90AA1, disrupting its tumor-promoting and cytoprotective autophagy-stimulating functions. Genetic deletion of HSP90AA1 compromises aspirin’s inhibitory effects on CRC cells. Specifically, lysine 410 (K410) is identified as the specific site on HSP90AA1 acetylated by aspirin. HSP90AA1 with the K410Q acetylation mimetic loses its abilities to promote tumorigenesis and cytoprotective autophagy. Furthermore, aspirin treatment induces enhanced ubiquitination and degradation of ULK1, a key regulator of autophagy initiation, attributed to the reduced interaction between HSP90AA1 and ULK1 resulting from K410 acetylation of HSP90AA1 triggered by aspirin. Our findings elucidate the role of aspirin in inhibiting cytoprotective autophagy in CRC and provide novel mechanistic insights into its tumor-suppressing capabilities, suggesting a promising therapeutic approach against CRC involving aspirin and the targeting of HSP90AA1 acetylation.

  • Open Access

    Macrophage-specific TRAF6 deletion mitigates DSS-induced colitis and is associated with reduced Enterococcus abundance and altered arachidonic acid metabolism

    by Qinmei Ma, Fang Li, Mingdi Wang, Xiuyi Fang, Jinhan Sun, Fang Wang, Xiaoling Wu, Yujing Gao

    Inflammatory bowel disease (IBD) involves dysregulated host immunity, gut microbial dysbiosis, and metabolic disturbances. As key innate immune cells, macr

  • Open Access

    An explainable machine learning framework integrating clinical and lipidomic signatures for early severity stratification of hypertriglyceridemic pancreatitis

    by Yanrong Yao, Bo Yuan, Kai Wang, Chensi Zhao, Jiazheng Yang, Jingli Liu, Zuozheng Wang, Yujing Gao

    Background: Hypertriglyceridemic pancreatitis (HTGP) is increasingly recognized as a major etiology of acute pancreatitis and is associated with a higher risk of early severe progression, systemic complications, and mortality compared with other etiologies. However, currently available scoring systems demonstrate limited accuracy and poor mechanistic interpretability in HTGP. Aim: To develop and validate an explainable machine learning model for early stratification of severe progression in HTGP and to explore its underlying lipidomic mechanisms. Methods: A retrospective cohort of 288 patients with HTGP admitted between 2020 and 2025 was included. Patients were categorized into mild acute pancreatitis (MAP) and moderately severe/severe acute pancreatitis (MSAP/SAP). Ensemble feature selection integrating eight algorithms was applied to identify robust predictors. Ten machine learning models were constructed and compared. SHAP (SHapley Additive exPlanations) analysis was used to interpret model outputs. Untargeted serum lipidomics combined with KEGG pathway enrichment analysis was performed in 15 matched severe/non-severe AP pairs to explore the biological relevance of identified predictors. Results: Among 288 patients, 150 (52.1%) were classified as MSAP/SAP at hospital admission. Ten predictors associated with inflammatory activation, coagulation dysfunction, endothelial leakage, and systemic injury were identified, including IL-6, D-dimer, PCT, albumin, CRP, SIRS, pleural effusion, and pancreatitis-associated ascitic fluid. Among all candidate algorithms, the Naive Bayes model achieved the best overall discrimination (AUC = 0.841), outperforming APACHE II and modified Marshall scores. Calibration assessment revealed a calibration intercept of −0.0332 and a Brier score of 0.2035; the calibration slope of 0.2009 indicated compression of predicted probabilities, suggesting caution in absolute risk estimation. Decision curve analysis demonstrated positive net clinical benefit across threshold probabilities from 0 to approximately 0.85, with the Naive Bayes model outperforming both benchmark scoring systems across clinically relevant thresholds. SHAP analysis identified IL-6, D-dimer, and PCT as the most influential predictors. Exploratory lipidomic pathway enrichment in a sub-cohort of 15 matched pairs identified alterations in glycerophospholipid metabolism, sphingolipid metabolism, necroptosis, and autophagy pathways, providing hypothesis-generating biological context for the identified clinical predictors. Conclusion: We developed an explainable machine learning framework integrating clinical and exploratory lipidomic evidence for early severity stratification of HTGP at hospital admission. The identified predictors converged on interconnected biological axes involving inflammation, coagulation, and endothelial dysfunction. The lipidomic sub-study provided complementary pathway-level context supporting the biological plausibility of these predictors. As this study is based on a single-center retrospective cohort without external validation, findings should be regarded as preliminary; prospective multicenter validation is required before clinical deployment.

  • Open Access

    Global Burden of Pulmonary Arterial Hypertension in Older Adults and Its Causal Association With Body Mass Index

    by Yajuan Fu, Baohong Wang, Fang Li, Xinmin Tian, Jiwei Gu, Yujing Gao

    Pulmonary arterial hypertension (PAH) is a severe cardiopulmonary disease associated with substantial morbidity and mortality. However, the global burden, future trajectory, and potentially modifiable risk factors for PAH among older adults remain insufficiently characterized. This study aimed to quantify the global burden and projected trends of PAH among adults aged ≥ 60 years and investigate the causal association between body mass index (BMI) and PAH risk using Mendelian randomization (MR). We extracted PAH burden estimates from the Global Burden of Disease (GBD) 2021 study across 204 countries and territories, 21 GBD regions, and five socio‐demographic index (SDI) strata. Temporal trends were assessed using age‐standardized rates and average annual percent changes (AAPCs), while demographic decomposition and Bayesian age‐period‐cohort (BAPC) models were applied to evaluate drivers of burden changes and future trajectories. Two‐sample MR analyses were performed using genome‐wide significant BMI‐associated genetic variants as instrumental variables and PAH genome‐wide association study summary statistics from FinnGen. Between 1990 and 2021, global incident cases of PAH among adults aged ≥ 60 years increased from 6771.01 (95% uncertainty interval [UI]: 4577.81–9656.55) to 15,622.29 (95% UI: 10,546.44–22,296.65), and deaths increased from 6812.93 (95% UI: 5305.00–8473.04) to 15,443.42 (95% UI: 11,746.25–18,388.02). Although the age‐standardized mortality, prevalence, and disability‐adjusted life year (DALY) rates declined, the age‐standardized incidence rate showed a slight increase (AAPC = 0.07%, 95% CI: 0.05–0.09). Marked geographic and SDI‐related disparities were observed, with population growth and aging identified as the predominant contributors to the rising absolute burden. BAPC modeling projected continued increases in absolute PAH cases through 2050 despite declining age‐standardized mortality and DALY rates. In addition, MR analyses provided suggestive evidence for a positive association between genetically predicted higher BMI and increased PAH risk (inverse‐variance weighted odds ratio [IVW OR] = 1.84, 95% CI: 1.11–3.05, p = 0.018). Among older adults, the global absolute burden of PAH has increased substantially over the past three decades and is expected to continue rising, largely driven by population aging and growth. Genetic evidence further suggests that elevated BMI may represent a potentially modifiable risk factor for PAH. These findings highlight the need for enhanced surveillance, improved diagnostic strategies, equitable healthcare access, and targeted metabolic risk management to address the growing burden of PAH in aging populations.

  • Open Access

    Wnt5a augments intracellular free cholesterol levels and promotes castration resistance in prostate cancer

    by Yuqi Guo, Zhiyuan Zhang, Lintao Dong, Xinyi Shi, Xiaohan Li, Mingxiu Luo, Yajuan Fu, Yujing Gao

    Prostate cancer (PCa) is a leading cause of cancer-related mortality in men globally. While androgen deprivation therapy (ADT) can extend the asymptomatic phase and overall survival of patients with metastatic PCa, prolonged ADT often leads to the development of castration-resistant prostate cancer (CRPC) within 18–24 months. The mechanisms underlying CRPC remain incompletely understood, presenting a significant challenge in clinical prostate cancer treatment. In this study, we investigated the role of Wnt5a, a member of the Wnt family, in CRPC. Tumor tissues from CRPC patients were analyzed to assess the expression levels of Wnt5a. Prostate cancer cells were used to examine the impact of Wnt5a on androgen-dependent and -independent growth, as well as sensitivity to bicalutamide. RNA-seq analysis, qRT-PCR, intracellular cholesterol content and the activation of the androgen receptor (AR) signaling pathway were evaluated to elucidate the mechanistic role of Wnt5a in CRPC progression. Drug target Mendelian randomization analysis was performed to investigate the effect of PCSK9 inhibitor on prostate cancer. Our study revealed a significant overexpression of Wnt5a in tissues from CRPC tumors. Wnt5a was found to enhance both androgen-dependent and -independent growth in prostate cancer cells while reducing their sensitivity to bicalutamide. Mechanistically, Wnt5a was shown to upregulate intracellular free cholesterol content and activate the AR signaling pathway, contributing to hormone therapy resistance in CRPC. PCSK9 inhibitor significantly reduced the risk of PCa. The findings of this study highlight a novel molecular mechanism underlying endocrine therapy resistance in CRPC mediated by Wnt5a. Targeting Wnt5a or reducing cholesterol level would be a promising therapeutic strategy for the treatment of CRPC, providing new insights into potential avenues for combating this challenging form of prostate cancer.


  • Open Access

    TFAP2A downregulation mediates tumor-suppressive effect of miR-8072 in triple-negative breast cancer via inhibiting SNAI1 transcription

    by Yujie Fang, Yali Wang, Hongning Ma, Yuqi Guo, Rongrong Xu, Xixi Chen, Xuehua Chen, Ye Lv, Pu Li, Yujing Gao

    Background: Triple-negative breast cancer (TNBC) represents a highly aggressive subset of breast malignancies characterized by its challenging clinical management and unfavorable prognosis. While TFAP2A, a member of the AP-2 transcription factor family, has been implicated in maintaining the basal phenotype of breast cancer, its precise regulatory role in TNBC remains undefined. Methods: In vitro assessments of TNBC cell growth and migratory potential were conducted using MTS, colony formation, and EdU assays. Quantitative PCR was employed to analyze mRNA expression levels, while Western blot was utilized to evaluate protein expression and phosphorylation status of AKT and ERK. The post-transcriptional regulation of TFAP2A by miR-8072 and the transcriptional activation of SNAI1 by TFAP2A were investigated through luciferase reporter assays. A xenograft mouse model was employed to assess the in vivo growth capacity of TNBC cells. Results: Selective silencing of TFAP2A significantly impeded the proliferation and migration of TNBC cells, with elevated TFAP2A expression observed in breast cancer tissues. Notably, TNBC patients exhibiting heightened TFAP2A levels experienced abbreviated overall survival. Mechanistically, TFAP2A was identified as a transcriptional activator of SNAI1, a crucial regulator of epithelial-mesenchymal transition (EMT) and cellular proliferation, thereby augmenting the oncogenic properties of TFAP2A in TNBC. Moreover, miR-8072 was unveiled as a negative regulator of TFAP2A, exerting potent inhibitory effects on TNBC cell growth and migration. Importantly, the tumor-suppressive actions mediated by the miR-8072/TFAP2A axis were intricately associated with the attenuation of AKT/ERK signaling cascades and the blockade of EMT processes. Conclusions: Our findings unravel the role and underlying molecular mechanism of TFAP2A in driving tumorigenesis of TNBC. Targeting the TFAP2A/SNAI1 pathway and utilizing miR-8072 as a suppressor represent promising therapeutic strategies for treating TNBC.


  • Open Access

    Modulation of intestinal metabolites by calorie restriction and its association with gut microbiota in a xenograft model of colorectal cancer

    by Yuhuan Zhang, Lintao Dong, Xingchen Dai, Yongli Huang, Yujing Gao, Fang Wang

    Background: Colorectal cancer (CRC) is a common malignant tumor, and its occurrence and development are closely related to dysbiosis of gut microbes. Previously, we found calorie restriction altered the composition of the microbial community in a colorectal cancer mouse model and inhibited in vivo growth of CRC cells. Here, we aim to further investigate alteration in the intestinal metabolites and explore the interplay between gut microbiota and intestinal metabolites upon calorie restriction. Methods: Human colorectal cancer HCT116 cells were used to establish a colorectal cancer xenograft mouse model. The changes of intestinal metabolites in the ad libitum group and calorie restriction group were investigated through untargeted metabolomics analysis. The integrative analysis of gut microbiota and metabolites to elucidate the associations between gut microbiota and intestinal metabolites. Results: Compared with the mice in the ad libitum group, mice upon calorie restriction exhibited downregulation of Isoleucyl-Valine, and upregulation of D-Proline, 1-Palmitoylphosphatidylcholine, and 4-Trimethylammoniobutanoic acid. Additionally, an integrative analysis of gut microbiota and metabolites revealed that Lactobacillus, Parabacteroides and rC4-4 genus were upregulated in the calorie restriction group and positively correlated with D-Proline, 4-Trimethylammoniobutanoic acid or 1-Palmitoylphosphatidylcholine, while negatively correlated with Isoleucyl-Valine. In contrast, the Nitrospirae and Deferribacteres phylum exhibited opposite trends. Conclusion: Calorie restriction affects the abundance of gut microbes such as Nitrospirae phylum and Lactobacillus genus in mouse model of colorectal cancer, leading to changes in the metabolites such as D-Proline、Isoleucyl-Valine, which contributes to the suppression of in vivo growth of CRC by calorie restriction.


  • Open Access

    Integrative analysis of transcriptomic and metabolomic profiles reveals enhanced arginine metabolism in androgen-independent prostate cancer cells

    by Xingchen Dai, Xinyi Shi, Mingxiu Luo, Pu Li, Yujing Gao

    Background: Prostate cancer is a common solid tumor that affects a significant number of men worldwide. Conventional androgen deprivation therapy (ADT) increases the risk of developing castration-resistant prostate cancer (CRPC). Effective clinical management of patients with CRPC is challenging due to the limited understanding. Methods: In this study, transcriptomic and metabolomic profiles of androgen-dependent prostate cancer cell line LNCaP and the androgen-independent cells developed from LNCaP cells (LNCaP-ADR) were investigated using RNA-sequencing and LC-MS/MS, respectively. The differentially expressed genes and metabolites were analyzed, and integrative analysis of transcriptomic and metabolomic data was further conducted to obtain a comprehensive understanding of the metabolic characteristics in LNCaP-ADR cells. Quantitative real-time PCR (QPCR) was employed to ascertain the mRNA expression levels of the selected differentially expressed genes. Results: The arginine and proline metabolism pathway was identified as a commonly altered pathway at both the transcriptional and metabolic levels. In the LNCaP-ADR cells, significant upregulation was observed for metabolites including 5-Aminopentanoic acid, L-Arginine, L-Glutamic acid, N-Acetyl-L-alanine, and Pyrrole-2-carboxylic acid at the metabolic level. At the transcriptional level, MAOA, ALDH3A2, ALDH2, ARG1, CKMT2, and CNDP1 were found to be significantly upregulated in the LNCaP-ADR cells. Gene set enrichment analysis (GSEA) identified various enriched gene sets in the LNCaP-ADR cells, encompassing inflammatory response, 9plus2 motile cilium, motile cilium, ciliary plasm, cilium or flagellum-dependent cell motility, cilium movement, cilium, response to endoplasmic reticulum stress, PTEN DN.V1 DN, SRC UP.V1 UP, IL15 UP.V1 DN, RB DN.V1 DN, AKT UP MTOR DN.V1 UP, VEGF A UP.V1 UP, and KRAS.LUNG.BREAST UP.V1 UP. Conclusions: These findings highlight the substantial association between the arginine and proline metabolism pathway and CRPC, emphasizing the need to prioritize strategies that target dysregulated metabolites and differentially expressed genes as essential interventions in the clinical management of CRPC.


  • Open Access

    Unveiling the role of ABI3 and hub senescence-related genes in macrophage senescence for atherosclerotic plaque progression

    by Yajuan Fu, Juan Zhang, Qiujun Liu, Lan Yang, Qianqian Wu, Xiaomin Yang, Lexin Wang, Ning Ding, Jiantuan Xiong, Yujing Gao, et al.

    Background: Atherosclerosis, characterized by abnormal arterial lipid deposition, is an age-dependent inflammatory disease and contributes to elevated morbidity and mortality. Senescent foamy macrophages are considered to be deleterious at all stages of atherosclerosis, while the underlying mechanisms remain largely unknown. In this study, we aimed to explore the senescence-related genes in macrophages diagnosis for atherosclerotic plaque progression. Methods: The atherosclerosis-related datasets were retrieved from the Gene Expression Omnibus (GEO) database, and cellular senescence-associated genes were acquired from the CellAge database. R package Limma was used to screen out the differentially expressed senescence-related genes (DE-SRGs), and then three machine learning algorithms were applied to determine the hub DE-SRGs. Next, we established a nomogram model to further confirm the clinical significance of hub DE-SRGs. Finally, we validated the expression of hub SRG ABI3 by Sc-RNA seq analysis and explored the underlying mechanism of ABI3 in THP-1-derived macrophages and mouse atherosclerotic lesions. Results: A total of 15 DE-SRGs were identified in macrophage-rich plaques, with five hub DE-SRGs (ABI3, CAV1, NINJ1, Nox4 and YAP1) were further screened using three machine learning algorithms. Subsequently, a nomogram predictive model confirmed the high validity of the five hub DE-SRGs for evaluating atherosclerotic plaque progression. Further, the ABI3 expression was upregulated in macrophages of advanced plaques and senescent THP-1-derived macrophages, which was consistent with the bioinformatics analysis. ABI3 knockdown abolished macrophage senescence, and the NF-κB signaling pathway contributed to ABI3-mediated macrophage senescence. Conclusion: We identified five cellular senescence-associated genes for atherogenesis progression and unveiled that ABI3 might promote macrophage senescence via activation of the NF-κB pathway in atherogenesis progression, which proposes new preventive and therapeutic strategies of senolytic agents for atherosclerosis.